alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › phosphorylation

phosphorylation

388 studies tagged phosphorylation, dated 1987-01-01 to 2026-10-31. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model 2026-10-31
  2. Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions 2026-10-30
  3. The Alzheimer's disease-associated rs28834970 variant in PTK2B impairs electrical activity and regulates Tau phosphorylation and APP processing in human neuronal cultures 2026-10-30

Studies

388 studies carry this tag.

Date range

1987 to 2026

Top journals

  • Acta neuropathologica 16
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 12
  • bioRxiv 12
  • Molecular neurodegeneration 10
  • Research Square 10

174 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2021-06-05 Drug development

    Phosphorylation is one of the most prevalent post-translational modifications found in aggregated tau isolated from Alzheimer's disease (AD) patient brains.

  2. Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biochemistry 2021-05-19 Drug development

    The microtubule-associated protein tau promotes the stabilization of the axonal cytoskeleton in neurons.

  3. Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. ACS applied materials & interfaces 2021-05-17 Drug development

    With the failure of various amyloid-β-targeted drugs for Alzheimer's disease (AD) in clinical trials, tau protein has gained growing attention as an alternative therapeutic target in recent years.

  4. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Science translational medicine 2021-05-01 Drug development

    Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD).

  5. Reducing acetylated tau is neuroprotective in brain injury

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cell 2021-04-13 Biomarkers

    Traumatic brain injury (TBI) is the largest non-genetic, non-aging related risk factor for Alzheimer's disease (AD).

  6. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain : a journal of neurology 2021-03-01 Biomarkers

    Tau is a microtubule associated protein in the brain that aggregates in Alzheimer's disease to form pathological tangles and neurites.

  7. Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceuticals (Basel, Switzerland) 2021-01-30 Brain scans and imaging

    Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology.

  8. Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in neurology 2021-01-07 Digital health tools

    Post-translational modifications (PTMs) on tau have long been recognized as affecting protein function and contributing to neurodegeneration.

  9. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International Journal of Biological Sciences 2021-01-01 Inflammation and the immune system

    Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of Alzheimer's disease (AD), and the separate neurotoxicity of these proteins in AD has been extensively studied.

  10. Reward motivation and cognitive flexibility in tau null-mutation mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of aging 2020-12-23 Drug development

    The reduction of tau or hyperphosphorylated tau (p-tau) has been proposed as a therapeutic strategy for Alzheimer's disease (AD) and frontotemporal dementia (FTD).

  11. Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of aging 2020-12-08 Disease mechanisms

    Accumulation of phosphorylated tau (p-tau) has long been an underappreciated hallmark of Alzheimer's disease.

  12. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta pharmacologica Sinica 2020-12-02 Treatments

    As the population ages, Alzheimer's disease (AD), the most common neurodegenerative disease in elderly people, will impose social and economic burdens to the world.

  13. Targeting Tau to Treat Clinical Features of Huntington's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in neurology 2020-11-19 Drug development

    Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by severe motor, cognitive and psychiatric impairments.

  14. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cell 2020-11-13 Genetics

    To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of 95 PTMs on multiple isoforms of Tau isolated from postmortem human tissue from 49 AD and 42 control subjects.

  15. Phosphorylated tau interactome in the human Alzheimer's disease brain

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain : a journal of neurology 2020-09-01 Genetics

    Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease.

  16. Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature communications 2020-05-26 Brain scans and imaging

    Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (Aβ).

  17. Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer's disease

    ⚠ Retracted — do not rely on it alzhub usefulness score 15 out of 100. Journal of nanobiotechnology 2020-05-13 Drug development

    Intravenous neuronal tau-targeted T807-modified novel biomimetic nanosystems are a promising clinical candidate for the treatment of AD.

  18. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Molecular psychiatry 2020-05-04 Drug development

    Neurofibrillary tangles (NFTs) composed of hyperphosphorylated and misfolded tau protein are a pathological hallmark of Alzheimer's disease and other tauopathy conditions.

  19. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Science advances 2020-04-15 Biomarkers

    The links between β-amyloid (Aβ) and tau in Alzheimer's disease are unclear.

  20. Circadian and sleep/wake-dependent variations in tau phosphorylation are driven by temperature

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Sleep 2020-04-15 Risk factors

    We found that tau phosphorylation undergoes sleep-driven circadian variations as it is hyperphosphorylated during sleep but not during acute sleep deprivation.

  21. Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Nature communications 2020-03-13 Biomarkers

    The relationship between amyloid-β (Aβ) species and tau pathology in Alzheimer's disease (AD) is not fully understood.

  22. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuropathology and experimental neurology 2020-03-01 Brain tissue and pathology

    Distinct neuronal and glial tau pathologies define corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP).

  23. TDP-43: From Alzheimer's Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in molecular neuroscience 2020-02-28 Brain tissue and pathology

    Since the discovery of TAR DNA-binding protein 43 (TDP-43) in 1995, our understanding of its role continues to expand as research progresses.

  24. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of neuroinflammation 2020-02-24 Biomarkers

    Our findings highlight sexual dimorphism in the behavior, neuropathology, and plasma proteins in tau P301S transgenic AD mice, indicating that the use of male P301S transgenic mice may be more suitable for assessing anti-phosphorylated tau therapeutic strategies for AD and related tauopathies, and the MIP-3α may be a new potential plasma biomarker.

  25. Novel tau filament fold in corticobasal degeneration

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature 2020-02-12 Genetics

    Corticobasal degeneration (CBD) is a neurodegenerative tauopathy-a class of disorders in which the tau protein forms insoluble inclusions in the brain-that is characterized by motor and cognitive disturbances 1-3 .

  26. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Expert opinion on pharmacotherapy 2020-02-08 Drug development

    Alzheimer's disease (AD) is a major cause of morbidity worldwide and its prevalence is expected to rise.

  27. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta neuropathologica communications 2020-02-04 Drug development

    Tau deposition in the brain is a pathological hallmark of many neurodegenerative disorders, including Alzheimer's disease (AD).

  28. Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in aging neuroscience 2020-01-14 Drug development

    Programmed cell death protein 1 (PD-1) checkpoint blockade with an antibody has been shown to reduce amyloid-β plaques, associated pathologies and cognitive impairment in mouse models.

  29. Altered Proteostasis in Neurodegenerative Tauopathies

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Advances in experimental medicine and biology 2020 Disease mechanisms

    Tauopathies are a heterogeneous group of neurodegenerative dementias involving perturbations in the levels, phosphorylation or mutations of the neuronal microtubule-binding protein Tau.

  30. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current Alzheimer research 2020 Drug development

    LMTM given alone increased hippocampal Acetylcholine (ACh) levels, glutamate release from synaptosomal preparations, synaptophysin levels in multiple brain regions and mitochondrial complex IV activity, reduced tau pathology, partially restored ChAT immunoreactivity in the basal forebrain and reversed deficits in spatial learning.

  31. Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Parkinson's disease 2020 Brain scans and imaging

    We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms.

  32. The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. International journal of molecular sciences 2019-12-14 Vascular contributions

    Cerebral amyloid angiopathy (CAA) is typified by the cerebrovascular deposition of amyloid.

  33. Amyloid-β-independent regulators of tau pathology in Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neuroscience 2019-11-28 Genetics

    The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease.

  34. Reduced expression of dMyc mitigates TauV337M mediated neurotoxicity by preventing the Tau hyperphosphorylation and inducing autophagy in Drosophila

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neuroscience letters 2019-11-09 Disease mechanisms

    Tauopathies such as Alzheimer's disease (AD), Pick's disease (PiD), Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) etc. represent a group of age-related neurodegenerative disorders in which tau protein loses its normal conformation mostly due to hyperphosphorylation and subsequent formation of the aggregates of defined shapes, known as Neurofibrillary Tangles (NFTs).

  35. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Acta neuropathologica 2019-11-04 Drug development

    The term "propagon" is used to define proteins that may transmit misfolding in vitro, in tissues or in organisms.

  36. [18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Acta neuropathologica communications 2019-10-28 Brain scans and imaging

    Despite the presence of abundant tau aggregates in multiple regions in all CTE brains, only faint or no [18F]-AV-1451 binding signal could be detected by autoradiography.

  37. [Anti-tau therapies-what can be expected?]

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Der Nervenarzt 2019-09 Drug development

    Alzheimer's disease is histopathologically characterized by aggregation of two proteins, namely amyloid-beta peptide and tau protein.

  38. Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. ACS chemical neuroscience 2019-08-05 Brain scans and imaging

    [18F]AV-1451 is one of the most widely used radiotracers for positron emission tomography (PET) imaging of tau protein aggregates in neurodegenerative disorders.

  39. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cell reports 2019-08-01 Brain scans and imaging

    Complement pathway overactivation can lead to neuronal damage in various neurological diseases.

  40. Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. ACS omega 2019-07-29 Drug development

    The Alzheimer's disease (AD) therapeutic research is yielding a large number of potent molecules.

  41. Discovery and preclinical characterization of [ 18 F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of nuclear medicine and molecular imaging 2019-07-01 Brain scans and imaging

    [ 18 F]PI-2620 was selected for clinical validation.

  42. Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Scientific reports 2019-06-25 Drug development

    The microtubule-associated protein tau is an attractive therapeutic target for the treatment of Alzheimer's disease and related tauopathies as its aggregation strongly correlates with disease progression and is considered a key mediator of neuronal toxicity.

  43. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain : a journal of neurology 2019-06-01 Drug development

    Tauopathies are neurodegenerative diseases characterized by the intraneuronal accumulation of aggregated tau.

  44. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biochemical Society transactions 2019-05-13 Prevention trials

    The identification of genetic forms of Parkinson's disease (PD) has tremendously expanded our understanding of the players and mechanisms involved.

  45. Formaldehyde, Epigenetics, and Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Chemical research in toxicology 2019-04-19 Drug development

    Alzheimer's disease (AD) is the most common form of dementia.

  46. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. eLife 2019-03-25 Brain scans and imaging

    Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas.

  47. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Scientific reports 2019-03-15 Drug development

    Neurodegenerative diseases such as Alzheimer's disease are characterized by the progressive spreading and accumulation of hyper-phosphorylated tau protein in the brain.

  48. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of neural transmission (Vienna, Austria : 1996) 2019-02-14 Biomarkers

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein.

  49. Synergistic Effect of Amyloid-β and Tau Disrupts Neural Circuits

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. ACS chemical neuroscience 2019-01-31 Drug development

    Alzheimer's disease (AD) is characterized by the coexistence of amyloid-β (Aβ) plaques and tau-based neurofibrillary tangles.

  50. Tau PET imaging in neurodegenerative tauopathies-still a challenge

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Molecular psychiatry 2019-01-11 Brain scans and imaging

    The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common.

From across this tag

10 of the 388 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

All topic tags with their study counts